Inhibition of Calpain Prevents N-Methyl-d-aspartate-Induced Degeneration of the Nucleus Basalis and Associated Behavioral Dysfunction
- Volker Nimmrich,
- Robert Szabo,
- Csaba Nyakas,
- Ivica Granic,
- Klaus G. Reymann,
- Ulrich H. Schröder,
- Gerhard Gross,
- Hans Schoemaker,
- Karsten Wicke,
- Achim Möller and
- Paul Luiten
- Neuroscience Research, GPRD, Abbott, Ludwigshafen, Germany (V.N., G.G., H.S., K.W., A.M.); Departments of Molecular Neurobiology (C.N., I.G., P.L.) and Biological Psychiatry, University of Groningen (P.L.), Haren, The Netherlands; Neuropsychopharmacology Research Unit of Semmelweis University and Hungarian Academy of Sciences, Budapest, Hungary (C.N., R.S.); and Projektgruppe Neuropharmakologie, Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.)
- Address correspondence to:
Dr. Volker Nimmrich, Neuroscience Research, GPRD, Abbott, Knollstrasse, d-67061 Ludwigshafen, Germany. E-mail: volker.nimmrich{at}abbott.com
Abstract
N-Methyl-d-aspartate (NMDA) receptor-mediated excitotoxicity is thought to underlie a variety of neurological disorders, and inhibition of either the NMDA receptor itself, or molecules of the intracellular cascade, may attenuate neurodegeneration in these diseases. Calpain, a calcium-dependent cysteine protease, has been identified as part of such an NMDA receptor-induced excitotoxic signaling pathway. The present study addressed the question of whether inhibition of calpain can prevent neuronal cell death and associated behavioral deficits in a disease-relevant animal model, which is based on excitotoxic lesions of the cholinergic nucleus basalis magnocellularis of Meynert. Excitotoxic lesions of the nucleus basalis with NMDA induced a markedly impaired performance in the novel object recognition test. Treatment with the calpain inhibitor, N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethlyaminomethylphenyl) ethen-1-yl]benzamide (A-705253), dose-dependently prevented the behavioral deficit. Subsequent analysis of choline acetyltransferase in the cortical mantle of the lesioned animals revealed that application of A-705253 dose-dependently and significantly attenuated cholinergic neurodegeneration. Calpain inhibition also significantly diminished the accompanying gliosis, as determined by immunohistochemical analysis of microglia activation. Finally, inhibition of calpain by A-705253 and the peptidic calpain inhibitor N-acetyl-Leu-Leu-Nle-CHO did not impair long-term potentiation in hippocampal slices, indicating that calpain inhibition interrupts NMDA excitotoxicity pathways without interfering with NMDA receptor-mediated signaling involved in cognition. We conclude that inhibition of calpains may represent a valuable strategy for the prevention of excitotoxicity-induced neuronal decline without interfering with the physiological neuronal functions associated with learning and memory processes. Thus, calpain inhibition may be a promising and novel approach for the treatment of various neurodegenerative disorders.
Footnotes
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.108.142679.
-
ABBREVIATIONS: NMDA, N-methyl-d-aspartate; A-705253, N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethlyaminomethylphenyl) ethen-1-yl]benzamide; NBM, nucleus basalis magnocellularis; LTP, long-term potentiation; PBS, phosphate-buffered saline; MK-801, 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10imine; ALLN, N-acetyl-Leu-Leu-Nle-CHO; ChAT, choline acetyltransferase; fEPSP, field excitatory postsynaptic potential; SBDP, spectrin breakdown product; APV, (2R)-amino-5-phosphonovaleric acid.
-
↵
The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
-
- Received June 25, 2008.
- Accepted August 12, 2008.
- The American Society for Pharmacology and Experimental Therapeutics



